^Original-Research: Cantourage Group SE - from NuWays AG14.04.2025 / 09:00 CET/CESTDissemination of a Research, transmitted by EQS News - a service of EQSGroup.The issuer is solely responsible for the content of this research. Theresult of this research does not constitute investment advice or aninvitation to conclude certain stock exchange transactions.---------------------------------------------------------------------------Classification of NuWays AG to Cantourage Group SE Company Name: Cantourage Group SE ISIN: DE000A3DSV01 Reason for the research: Update Recommendation: BUY from: 14.04.2025 Target price: EUR 13.00 Target price on sight of: 12 months Last rating change: Analyst: Christian SandherrGrowth beating expectations, again; PT upQ1 sales surged to EUR 25.6m, more than quadrupling compared to the previousyear's figure of EUR 6.1m and clearly exceeding our expectations of EUR 22m.Sequentially, sales grew by 21% qoq, marking a new record high. In Marchalone, sales stood at EUR 10.7m, beating the previous best month, Decemberwith EUR 8.5m. This increase should largely be the result of successfulde-bottlenecking efforts on Cantourage's side during the past few months.With strongly growing demand, the company has been working on raising itsprocessing capacities at it German site as well as through partnerships(e.g. with a Portuguese contract manufacturer). Securing sufficient supply(incl. processing capacities) could allow Cantourage to reach the EUR 100msales level already this year.Scale to kick in. While Cantourage only announced sales figures, we wouldalso expect a further improving margins as scale effects begin to kick in.We would expect an EBITDA margin of around 10% to be in the cards (for Q1)despite ongoing investments into growth.No FY25 guidance issued yet. So far, management has not issued a guidancefor the current year. We would expect a first FY25 outlook with thepublication of final FY24 figures at the end of April. In light of thebetter than expected start into the year, unbroken demand and furtherde-bottlenecking efforts, we have increased our sales growth expectationsfrom 67% to 81%, implying EUR 93m sales.Easing political risks. Last week, Germany's new government published thecoalition agreement, which states an open-ended evaluation of the cannabislegalization law for autumn 2025. In our view, this is a clear positive anda return to the pre-April 1st, 2024 legal framework or a reclassification ofcannabis as a narcotic now appears increasingly unlikely, not only due tothe high degree of complexity as well as a wave of lawsuits but also aseemingly low importance to the new law-makers (postponed discussions andonly one sentence across a 146 page document).Share price de-coupled from fundamentals. While operations have beenstrongly improving quarter over quarter for roughly a year, the valuationhas decreased to some EUR 56m. Despite expected FY25e sale growth of 81% yoy,Cantourage should be able to reach a 10% EBITDA margin, implying anattractive EV/EBITDA multiple of 5.2x.We confirm our BUY rating with a new EUR 13 PT (EUR 12.50) based on DCF.You can download the research here: http://www.more-ir.de/d/32238.pdfFor additional information visit our website:https://www.nuways-ag.com/research-feedContact for questions:NuWays AG - Equity ResearchWeb: www.nuways-ag.comEmail: research@nuways-ag.comLinkedIn: https://www.linkedin.com/company/nuwaysagAdresse: Mittelweg 16-17, 20148 Hamburg, Germany++++++++++Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschlussbestimmter Börsengeschäfte.Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim obenanalysierten Unternehmen befinden sich in der vollständigen Analyse.++++++++++---------------------------------------------------------------------------The EQS Distribution Services include Regulatory Announcements,Financial/Corporate News and Press Releases.Archive at www.eqs-news.com---------------------------------------------------------------------------2116712 14.04.2025 CET/CEST°